Panbela Therapeutics, Inc. · OTC:PBLA

Panbela Therapeutics — Investor Presentation (September 2023)

37 slides from Panbela Therapeutics's investor presentation, Sep 29, 2023

  1. Slide 1: Investor Presentation October 2023

    Investor Presentation October 2023 Last modified September 29, 2023 Panbela Therapeutics

  2. Slide 2: Disclaimers

    Disclaimers Certain statements in this presentation are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are provided under the protection of the safe harbor for forward-looking statements provided by that Act. Forward-looking statements are b

  3. Slide 3: Company Presents A Unique Opportunity: Multi-Targeted Approach to Reset Dysregulated Biology

    Company Presents A Unique Opportunity: Multi-Targeted Approach to Reset Dysregulated Biology Scientific focus on polyamines, key regulators of normal biology altered in many disease states 1  Multiple near term inflection points  CPP acquisition completed in 2022 to create complementary, multiprod

  4. Slide 4: Highly Experienced Management Team with Proven Track Record

    Highly Experienced Management Team with Proven Track Record Proven orphan and oncology drug discovery, development and commercialization expertise Dr. Jennifer Simpson Sue Horvath Dr. Elizabeth Bruckheimer Chief Executive Officer Chief Financial Officer VP, Chief Scientific Officer 15+ Years 15+ Yea

  5. Slide 5: Dysregulation of the Polyamine Pathway Leads to Disease

    Dysregulation of the Polyamine Pathway Leads to Disease Polyamine Dysregulation in Disease Cancer Autoimmune Diseases Pancreatic ductal adenocarcinoma Recent Onset Type 1 Diabetes Familial Adenomatous Polyposis (FAP) Colorectal Ovarian STK11 Mutant NSCLC Prostate Initial focus on oncology and autoim

  6. Slide 6: Pipeline May Address Multiple Unmet Needs

    Pipeline May Address Multiple Unmet Needs Preclinical IND Ready Phase I Phase II Phase III Milestones  Phase III Enrolling; PDA (First Line Metastatic) Interim Analysis Early (ivospemin) SBP-101 (Injection) 2024 PDA Neoadjuvant  Phase II Ready – Open 2H 2023 Ovarian  Phase I Ready – Open 2H 2023

  7. Slide 7: Potential Market Opportunity for Lead Programs

    Potential Market Opportunity for Lead Programs Pancreatic Cancer FAP Colorectal Cancer Ovarian Cancer Incidence of Incidence of Incidence of Incidence of Pancreatic Cancer FAP Colorectal Cancer Ovarian Cancer 64K in US ~30K in US ~150K in US ~22K in US ~151K in EU ~50K in EU ~340K in EU ~79K in EU ~

  8. Slide 8: Complementary Pharmacotherapies Targeting Dysregulation

    Complementary Pharmacotherapies Targeting Dysregulation Pipeline Objective Combined pipeline pharmacotherapies hit different targets in the polyamine pathway The objective of Panbela’s pipeline is the utilization of pharmacotherapies to reduce/normalize CPP-1X-T & CPP-1X-S increased disease- associa

  9. Slide 9: Ivospemin (SBP-101)

    Ivospemin (SBP-101) Panbela Therapeutics 9

  10. Slide 10: Preliminary Efficacy of ivospemin (SBP-101) + Gemcitabine/Nab-paclitaxel in First-Line Metastatic PDA

    Preliminary Efficacy of ivospemin (SBP-101) + Gemcitabine/Nab- paclitaxel in First-Line Metastatic Pancreatic Ductal Adenocarcinoma BEST OVERALL RESPONSE Overall Disease CR PR SD PD Response Control Ivospemin (0.40 mg/kg) + G/A* (Ph Ia COHORT 2) 0 5 (71%) 2 (29%) 0 5/7 (71%) 5/7 (71%) n=7 ivospemin

  11. Slide 11: Efficacy Comparison of ivospemin (SBP-101) + Gemcitabine/Nab-paclitaxel vs. Standard of Care

    Efficacy Comparison of ivospemin (SBP-101) + Gemcitabine/Nab- paclitaxel vs. Standard of Care Treatment OS PFS ORR DCR PD CL-SBP-101-031 14.6 months 6.5 months 48.3% 82.8% 4.8% FOLFIRINOX2 11.1 months 6.4 months 31.6% 70.2% 15.2% Modified FOLFIRINOX3 10.2 months 6.1 months 35.1% 86.5% 13.5% NALIRIFO

  12. Slide 12: Phase I Trial Efficacy of SBP-101 + Gemcitabine/Nab-paclitaxel

    Phase I Trial Efficacy of SBP-101 +Gemcitabine/Nab-paclitaxel Progression-Free Overall Survival Survival (PFS) (OS) Median PFS=6.5 Median OS=14.8 months months • Cumulative survival rates at 6 and 12 months were 86.2% and 55.2%. with 3 subjects (10.3%) alive at 19.6, 20.1, and 22.9 months. • The cum

  13. Slide 13: Safety Results

    Ivospemin (SBP-101) + Gemcitabine/Nab-paclitaxel Demonstrated a Similar Safety Profile to Gemcitabine/Nab-paclitaxel in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Safety Results Grade ≥3 AEs of Special SBP- Grade ≥3 adverse events attributable to any study medication, N G+A %** Interest

  14. Slide 14: Phase III Pancreatic Cancer Trial in Previously Untreated Metastatic PDA

    Phase III Pancreatic Cancer Trial in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma A Randomized, Double-Blind, Placebo Controlled Study of Nab-Paclitaxel and Gemcitabine with or Without ivospemin (SBP-101) OS-Overall Survival PFS-Progression Free Survival ORR – Overal

  15. Slide 15: FLYNPOVI: A Combination of CPP-1X and Sulindac

    FLYNPOVI: A Combination of CPP-1X and Sulindac Panbela Therapeutics 15

  16. Slide 16: Lead Product Opportunity – CPP-1X and Sulindac (Flynpovi)

    Lead Product Opportunity – CPP-1X and Sulindac (Flynpovi) Familial Adenomatous Key Information: Polyposis (FAP)  No approved FAP drugs on the market  A genetic disease  Target Physicians: Gastroenterologists caused by APC  US-only potential revenue at market share of 35%-60% mutations where (app

  17. Slide 17: FAP-310 Trial: Time to Delay FAP-related Event Endpoint

    FAP-310 Trial: “Time to Delay FAP-related Event” Endpoint CPP FAP 310 global study 150 Patients Required (171 Patients Enrolled) Time to delay FAP-related events Composite Endpoint including surgeries, polyp removal, 1:1:1 Randomization and upper GI scoring system (“Spigelman”)*; based on FDA/EMA re

  18. Slide 18: No Lower GI Surgeries for Flynpovi Combination

    No Lower GI Surgeries for Flynpovi Combination Event Rate Distribution of FAP-Related Surgery Events in Lower GI Surgery Events ES Combo Eflornithine Sulindac Overall (N=56) (N=57) (N=58) (N=171) Need colectomy 0 3 4 7 Need proctectomy 0 1 1 2 Need pouch resection 0 4 1 5 Total Surgical Events 0 8 6

  19. Slide 19: Flynpovi Combination Delays Need for Lower GI Surgery

    Flynpovi Combination Delays Need for Lower GI Surgery Delay in Lower GI Surgery Events (Vertical hashmarks “|” denote when patient comes off study) 100 Subjects Event Free (%) 90 80 Treatment Groups 70 ES Sulindac 60 Eflornithine 50 0 6 12 18 24 30 36 42 48 Time from Randomization Date to FAP-relate

  20. Slide 20: Rationale for Efficacy of Flynpovi in the Lower Gastrointestinal Tract of FAP Patients

    Rationale for Efficacy of Flynpovi in the Lower Gastrointestinal Tract of FAP Patients Microbiome Diet MYC Growth/Tissue APC MAD1 ODC Put Polyamines Repair/Neoplasia K-RAS  Polyamines can by synthesized but also derived from the diet and microbiome.  The microbiota increases steadily along the gas

  21. Slide 21: Adverse Events of Special Interest

    Adverse Events of Special Interest Flynpovi (Eflornithine + Sulindac Sulindac Eflornithine Adverse Events of Special Combination) N=57 N=56 Interest N=56 Subjects (%) Subjects (%) Subjects (%) Anemia 1 (1.8) 5 (8.8) 2 (3.6) Myelosuppression 0 1 (1.8) 0 Thrombocytopenia 0 3 (5.3) 1 (1.8) Cardiovascul

  22. Slide 22: Basis for FDA Complete Response Letter

    Basis for FDA Complete Response Letter  Clinical  Single pivotal study efficacy was based on exploratory post-hoc analysis using a modified primary endpoint in a subgroup of the intent-to treat population o Asked to perform a new study focused on FAP patients with an intact lower-GI tract which sh

  23. Slide 23: Summary of Approach to Approval

    Summary of Approach to Approval Strong Results in the Lower GI  Focus on Lower GI: statistically significant p-values and hazard ratios for clinically meaningful surgical endpoints—emphasized by regulators—in Phase III pivotal trial  Expected safety profile over 2-4 years of daily dosing in Phase

  24. Slide 24: Polyamines & Immune Dysregulation

    Polyamines & Immune Dysregulation Panbela Therapeutics 24

  25. Slide 25: Role of Polyamines in Immune Dysregulation

    Role of Polyamines in Immune Dysregulation  Immune systems require multiple soluble and cellular components, including polyamines, for a normal immune function  High levels of polyamines are present in tumor cells and in autoreactive B- and T- cells in autoimmune diseases  Dysregulation of polyam

  26. Slide 26: Potential Role of Polyamines in DLBCL CAR-T Therapy

    Potential Role of Polyamines in Diffuse Large B Cell Lymphoma (DLBCL) CAR-T Therapy  Polyamine metabolism upregulation through oncogenic MYC is a common metabolic irregularity in aggressive cancers, including lymphomas.  MYC overexpression in relapsed/refractory DLBCL prior to CAR-T cell therapy n

  27. Slide 27: Rationale for Eflornithine/anti-PD-1 Combination

    Rationale for Eflornithine/anti-PD-1 Combination  Targeting Ornithine decarboxylase (ODC) using eflornithine unmasks antitumor T cell immune response by weakening of tumor-induced immune suppression that is mediated by Myeloid-Derived Tumor Suppressor Cells (MDSCs).  The addition of anti-PD-1 prev

  28. Slide 28: CPP-1X-S

    CPP-1X-S Panbela Therapeutics 28

  29. Slide 29: Rationale for CPP-1X-S (Eflornithine Sachets) in STK11 Mutant NSCLC

    Rationale for CPP-1X-S (Eflornithine Sachets) in STK11 Mutant NSCLC  In preclinical tumor models, eflornithine treatment improves anti-PD-1 efficacy by:  Increasing tumor-specific cytotoxic T-cell populations  Increasing expression of PD-1 on tumor-associated CD8+ T cells  ~10% of NSCLC cancers

  30. Slide 30: STK11 Mutant NSCLC Investigator-Initiated Trial

    STK11 Mutant NSCLC Investigator-Initiated Trial Collaborating with investigators at Moffitt Cancer Center on Phase I/II trial: “Targeting Ornithine Decarboxylase as an Immunotherapeutic Target in STK11 (LKB1) Pathway- Deficient Non-Small Cell Lung Cancer” Patient Population Phase I Phase II  Stage

  31. Slide 31: Business Overview

    Business Overview Panbela Therapeutics 31

  32. Slide 32: Barriers to Entry – Flynpovi/CPP-1X

    Barriers to Entry – Flynpovi/CPP-1X  Orphan status (7 years exclusivity US; 10 years exclusivity EU) for CPP-1X ◦ Granted in US and EU for FAP ◦ Granted in US for Gastric cancer and Pancreatic cancer  Pharmaceutical Composition Patent ◦ Fixed dose combination eflornithine + sulindac ◦ Broadly nati

  33. Slide 33: Barriers to Entry – ivospemin (SBP-101)

    Barriers to Entry – ivospemin (SBP-101)  Orphan status (7 for years exclusivity US; 10 years exclusivity EU) for SPB-101 ◦ Granted in US and EU for pancreatic cancer  METHODS FOR PRODUCING (6S,15S)-3,8,13,18-TETRAAZAICOSANE-6,15-DIOL ◦ PCT application filed January 29, 2019 ◦ Granted in United Sta

  34. Slide 34: Summary of Milestones

    Summary of Milestones 1H 2023  Open- Phase I NSCLC Trial  Open- Neoadjuvant Pancreatic Cancer Trial  Open – Phase II Type I onset Diabetes Trial  Futility Analysis Phase III Colon Cancer Risk Reduction Trial (PACES) 2H 2023  Prespecified Safety Analysis by DSMB for the Aspire Trial  Publicatio

  35. Slide 35: Financial Position - Cash and Debt (unaudited)

    Financial Position - Cash and Debt (unaudited) Cash and Debt Cash at 6/30/2023 7,205,000 Debt at 6/30/2023 Current (due 1/31/2024) 1,000,000 Non-current 4,194,000 Total 5,194,000 (1) Proforma Cash consists of 12/31/22 balance plus disclosed equity transactions subsequent to 12/31/22. Does not reflec

  36. Slide 36: Capital Stock (unaudited)

    Capital Stock (unaudited) Panbela Common Stock at 6/30/2023 2,612,038 Shares issued in exchange for warrants 7/1/2023 to 8/10/2023 84,744 Prefunded warrants exercised 7/1/2023 to 8/10/2023 260,954 Total Proforma Common stock outstanding 2,957,736 Shares reserved for Options (WAE = $1,071.08) at 6/30

  37. Slide 37: Summary: Broad, late-stage de-risked pipeline opportunities

    Summary: Unique Scientific Approach: Resetting dysregulation via polyamine pathway Broad, late-stage de-risked pipeline opportunities Multiple partnerships supporting development programs Significant market potential Multiple data readouts expected Experienced management team Panbela Therapeutics 37

Panbela Therapeutics — Investor Presentation (September 2023) on 6ix